Cronos Group Inc (CRON)vsViatris Inc (VTRS)
CRON
Cronos Group Inc
$3.14
-0.63%
HEALTHCARE · Cap: $1.16B
VTRS
Viatris Inc
$16.51
+0.79%
HEALTHCARE · Cap: $19.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 8129% more annual revenue ($14.74B vs $179.09M). CRON leads profitability with a 39.1% profit margin vs -2.8%. CRON earns a higher WallStSmart Score of 61/100 (C+).
CRON
Buy61
out of 100
Grade: C+
VTRS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CRON.
Margin of Safety
-85.0%
Fair Value
$8.72
Current Price
$16.51
$7.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 39 of every $100 in revenue as profit
Revenue surging 58.4% year-over-year
Earnings expanding 126.8% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
ROE of -0.2% — below average capital efficiency
4.9% revenue growth
ROE of -2.9% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : CRON
The strongest argument for CRON centers on Price/Book, Profit Margin, Revenue Growth. Profitability is solid with margins at 39.1% and operating margin at 15.4%. Revenue growth of 58.4% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.
Bear Case : CRON
The primary concerns for CRON are Market Cap, Return on Equity.
Bear Case : VTRS
The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.
Key Dynamics to Monitor
CRON profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.
CRON carries more volatility with a beta of 1.28 — expect wider price swings.
CRON is growing revenue faster at 58.4% — sustainability is the question.
VTRS generates stronger free cash flow (329M), providing more financial flexibility.
Bottom Line
CRON scores higher overall (61/100 vs 48/100), backed by strong 39.1% margins and 58.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cronos Group Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Cronos Group Inc. is a cannabinoid company. The company is headquartered in Toronto, Canada.
Visit Website →Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?